New drug plus hormone therapy for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage or locally advanced breast cancer (stage I-III) that is HR-positive and HER2-positive
- You are a woman between 18 and 75 years old
- Your overall health and organ function (blood counts, liver, kidney, heart) meet specific safety thresholds
- You are able to swallow capsules and have no severe swallowing problems
- You have not had major surgery, radiation, or other cancer treatments in the past 4 weeks
- You do not have uncontrolled high blood pressure, diabetes, heart disease, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This trial tests a new oral medicine combined with a standard hormone therapy for advanced hormone-receptor-positive, HER2-negative breast cancer. The goal is to see if the combination can help control the cancer better than hormone therapy alone.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.